(Q73722395)
Statements
Clinical Benefit within Patient Subgroups Receiving c7E3 Fab (Abciximab) During Percutaneous Coronary Revascularization: Subgroup Analysis from the EPIC Trial (English)
Topol EJ
1 reference
Aguirre FV
Anderson KM
Kleiman NS
Weisman HF